

10 April 2018

HAPA TRANSACTION UPDATE

The Directors of 1-Page Limited (**Company**) are pleased to provide an update on the conditional binding agreement to acquire 100% of the parent company of the HAPA Medical Group based in Germany (**HAPA**), as announced on 2 February 2018.

The cash payments required under the conditional binding agreement have now been made and the company is moving toward relisting as soon as possible. To this end the Company is currently in discussion with ASX in relation to the requirements for completing the transaction and will provide further updates when it is able to confirm the final timing. At this stage, the Company expects to be lodging a Notice of Meeting in May for a shareholder meeting to be held the following month to approve the transaction. This then allows for a re-compliance prospectus to be issued and, subject to ASX approval, the Company to be re-instated to trading as European Cannabis Corporation Ltd (“EuroCann”) shortly thereafter.

Over this time HAPA has continued to meet targets with key highlights as follows:

- HAPA opened Germany’s first specialist medical cannabis clinic in Berlin on 1 March 2018.
- HAPA has successfully introduced its GMP-grade CBD products into the German market with its first batch of test products sold out generating revenues in excess of EUR100,000 with a second, larger batch currently being manufactured off the back of this success.
- Ongoing progress being made with regard to obtaining necessary narcotics licences to be able to sell GMP-grade THC containing medicinal cannabis based products.
- Ongoing discussions with numerous suppliers of raw material and finished product to diversify sources of supply.
- Executive team has been expanded.

“We continue to be impressed with the performance of the HAPA group since finalising the conditional binding agreement. The HAPA Group have been delivering on the goals that have been set and are moving rapidly to leverage their early mover advantage. There has been a strong take up as shown with the first test batch of CBD products being sold very quickly and the current status of the various licences required to operate progressing as planned” said 1-Page’s Non-executive Chairman Tod McGrouther.

Background on HAPA

HAPA is an early mover in the German medicinal cannabis market and is focused on offering its own pharmaceutical GMP-grade THC & CBD product lines to German patients through a HAPA owned network of medical cannabis clinics throughout Germany.

Following changes to Germany’s laws in 2017, the medicinal cannabis market is quickly growing and HAPA has positioned itself to be at the forefront of these developments. The acquisition of HAPA provides the Company’s shareholders with an immediate exposure to the German medical cannabis market, with the opportunity for ongoing growth

END